GlassScriptPhysician profile
David W Goldfarb
NPI 1225265168
$35,109.60
in general payments reported to CMS, 2019-2025
62 companies · $11K in 2025
The $11K reported for 2025 was more than what 94% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,070 · 2020: $1,311 · 2021: $1,313 · 2022: $8,820 · 2023: $7,843 · 2024: $3,193 · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $6,100 · Long Term Medical Supply Or Device Loan: $5,143 · Entertainment: $18.94.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,333.38 |
| Education | $6,099.99 |
| Long Term Medical Supply Or Device Loan | $5,142.85 |
| Entertainment | $18.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $12,236.17 | 2022-2023 | Da Vinci Sp |
| Biotissue Holdings INC. | $5,175.65 | 2022-2025 | |
| Hmu Consumables, LLC | $5,142.85 | 2025 | Dornier Medtech |
| Boston Scientific Corporation | $2,712.94 | 2019-2025 | Ams 700, Spaceoar Vue System - 10ml, Advance Xp |
| Astellas Pharma US INC | $1,119.63 | 2019-2025 | Xtandi, Myrbetriq, Padcev |
| Sumitomo Pharma America, INC. | $927.52 | 2023-2025 | Gemtesa, Orgovyx |
| Terumo Medical Corporation | $771.34 | 2021-2023 | Tr Band, Hydropearl, Glidewire |
| Abbvie INC. | $744.43 | 2019-2025 | |
| Procept Biorobotics Corporation | $584.45 | 2021-2025 | Aquabeam System, Aquabeam Robotic System |
| Pfizer INC. | $580.41 | 2019-2025 | |
| Janssen Biotech, INC. | $539.46 | 2019-2025 | Erleada |
| Myriad Genetic Laboratories, INC. | $464.65 | 2020-2024 | Prolaris |
| Antares Pharma, INC. | $404.44 | 2019-2024 | Xyosted |
| Allergan, INC. | $301.22 | 2019-2022 | |
| Progenics Pharmaceuticals, INC. | $250.88 | 2021-2025 | Pylarify |
Show all 62 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$14,814.84 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Goldfarb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.